Monoclonal antibodies and fusion proteins in medicine

Slides:

Advertisements

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

What drives prescription patterns in pediatric asthma management?

“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events Keiichi Yamanaka, MD, PhD, Hitoshi.

Doina M. Racila, MD, Joel N. Kline, MD, MSc

Laurent L'homme, PhD, David Dombrowicz, PhD

Advances in food allergy in 2015

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Disparities in allergic disease: Hypersensitivity and social disorders

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

David J. Cousins, PhD, Joanne McDonald, BSc, Tak H. Lee, MD, ScD

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

The National Biome Initiative: An allergy perspective

Immune modulation by neuronal electric shock waves

Peter M. Wolfgram, MD, David B. Allen, MD

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

A survivor: The eosinophil as a regulator in asthma

Ricardo U. Sorensen, MD, Luke A. Wall, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Weiguo Chen, PhD, Gurjit K. Khurana Hershey, MD, PhD

Cephalosporin Side Chain Cross-reactivity

Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD

Mast cell granules: Modulating adaptive immune response remotely

Lora G. Bankova, MD, Joshua A. Boyce, MD

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Role of regulatory T cells and FOXP3 in human diseases

Autophagy: Nobel Prize 2016 and allergy and asthma research

Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Chemokines and their receptors in allergic disease

Prevention of food allergy: Beyond peanut

Cagri Yildirim-Toruner, MD, Betty Diamond, MD

One step forward, 2 steps back: The enigma of preschool wheeze

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Anaphylaxis Journal of Allergy and Clinical Immunology

Innate immune responses to infection

Endotoxin and the lung: Insight into the host-environment interaction

Measles and immunomodulation

Stefan Schülke, PhD, Stefan Vieths, PhD

Macrolide antibiotics and asthma treatment

Vitamin D in allergic disease: Shedding light on a complex problem

Asthma: The past, future, environment, and costs

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

Environmental factors and eosinophilic esophagitis

Adipose tissue, adipokines, and inflammation

Kinase inhibitors in clinical practice: An expanding world

Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases Susan Lee, MD, Mark Ballow, MD Journal of.

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Presentation transcript:

Monoclonal antibodies and fusion proteins in medicine Stamatis-Nick C. Liossis, MD, George C. Tsokos, MD Journal of Allergy and Clinical Immunology Volume 116, Issue 4, Pages 721-729 (October 2005) DOI: 10.1016/j.jaci.2005.06.035 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Biologic agents developed to disrupt lymphokine action. Immune cells produce cytokines that modulate the function of immune and nonimmune cells after binding to specific receptors. Humanized anti-cytokine mAbs form complexes with the respective cytokines and prevent their interaction with cell receptors. Decoy receptors bind circulating cytokines and prevent their interaction with cell-surface receptors. Journal of Allergy and Clinical Immunology 2005 116, 721-729DOI: (10.1016/j.jaci.2005.06.035) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Disruption of cognate immune cell interaction. T and B cells interact though multiple pairs of costimulatory molecules. Humanized mAbs directed against these molecules might effectively disrupt the T-B cell interaction. Alternatively, decoy receptors can, in a similar fashion, limit the cognate interaction. Antibodies or decoy receptors can disrupt the homing, inappropriate in the case of inflammatory diseases, of lymphocytes to inflamed tissues. Journal of Allergy and Clinical Immunology 2005 116, 721-729DOI: (10.1016/j.jaci.2005.06.035) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions